On Friday, Shares of Ascent Solar Technologies, Inc. (NASDAQ:ASTI), lost -1.29% to $0.153.
Ascent Solar Technologies, declared the brand’s expanded participation at the 2016 Consumer Electronics Show (CES) in Las Vegas.
“2016 is poised to be a year of rapid growth for EnerPlex both in product breadth and revenue,” said Justin R. Jacobs, Manager of Brand Development for EnerPlex & Ascent Solar. “CES is the perfect launch-pad for this growth; visitors to our exhibit will be treated to the next generation of mobility power in each of our key verticals: Mobile, Outdoor and Emergency Power.”
Mr. Jacobs continued, “Both EnerPlex and Ascent Solar continue to excel in pushing the boundaries of technological innovation, evidenced by our most recent US Patent award, the 2015 R&D 100 award and our litany of product design awards. This year at CES we will continue this tradition with the debut of new technology, products and product platforms which will facilitate growth in 2016.”
Ascent Solar Technologies, Inc., a development stage company, designs and manufactures photovoltaic integrated consumer electronics; and portable power applications for commercial and military users. The company offers Surfr, a battery and a solar case for the Apple iPhone 4/4S smart phone, in addition to for the Samsung Galaxy S III smart phone; EnerPlex Kickr, a portable solar charging device; and EnerPlex Jumpr, a portable power bank.
Shares of UnitedHealth Group Inc (NYSE:UNH), declined -2.82% to $115.86, during its last trading session.
Health services leader Optum declared that ProHealth Physicians (ProHealth), one of Connecticut’s largest independent physician groups and its integrated administration company, has joined the OptumCare organization to advance care for its more than 360,000 active patients.
ProHealth’s about 370 physicians and advanced practitioners provide primary care, specialty care and ancillary services.
Optum and ProHealth share a aim of improving the quality and efficiency of health care in local communities, and of managing the costs of care, by improving communication and partnership among patients, physicians, hospitals and health plans. Optum will assist ProHealth build upon its success with clinical and administrative support, counting access to advanced data, analytic and connectivity solutions that assist care providers better collaborate, coordinate care, and achieve the best possible outcomes. Optum also brings population health administration expertise to support better outcomes and healthy lifestyles, and front-office administrative services that assist physicians efficiently operate their practices and maintain their focus on patient care.
UnitedHealth Group Incorporated operates as a diversified health and well-being company in the United States. The company’s United Healthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; and health care coverage, and health and well-being services to individuals aged 50 and older addressing their needs for preventive and acute health care services.
Finally, Array Biopharma Inc (NASDAQ:ARRY), ended its last trade with -3.28% loss, and closed at $4.42.
Array BioPharma, stated top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial. The study met its primary endpoint of improving progression-free survival (PFS) contrast with dacarbazine treatment. The median PFS on the binimetinib arm was 2.8 months as contrast to 1.5 months on the dacarbazine arm; hazard ratio (HR) 0.62, [95% CI 0.47-0.80], p < 0.001.
In the trial, binimetinib was generally well-tolerated and the adverse events stated were compriseent with previous results in NRAS melanoma patients.
Array plans to submit binimetinib to regulatory authorities for marketing approval in NRAS-mutant melanoma during the first half of 2016. Results from the NEMO trial counting progression free survival, overall survival, objective response rate, safety and prespecified subgroup analyses counting outcomes in patients who received prior treatment with immunotherapy will be presented at a medical meeting in 2016.
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.